Becker Daniel J.

CIK 00017521395 companiesAGOURA HILLS, CA

SEC Profile

Transactions

Companies

Filings

CIK

0001752139

Recent Transactions

48 trades

Award
Zura Bio Ltd$ZURA
Share Option (Right to Buy)
2025-05-29+51,000→ 51,000 total
Disposition to Issuer
ACELYRIN, Inc.
Common Stock
2025-05-21−2,999→ 0 total
Disposition to Issuer
ACELYRIN, Inc.
Director Stock Option (right to buy)
2025-05-21−92,158→ 0 total
Disposition to Issuer
ACELYRIN, Inc.
Director Stock Option (right to buy)
2025-05-21−23,243→ 0 total
Sale
ACELYRIN, Inc.
Common Stock
2024-07-17$6.86/sh−1→ 2,999 total
Award
ACELYRIN, Inc.
Director Stock Option (right to buy)
2024-06-07+92,158→ 92,158 total
Award
Day One Biopharmaceuticals, Inc.$DAWN
Director Stock Option (Right to buy Common Stock)
2023-06-22+37,500→ 37,500 total
Purchase
ACELYRIN, Inc.
Common Stock
2023-05-09$18.00/sh+3,000→ 3,000 total
Other
ACELYRIN, Inc.
Director Stock Option (right to buy)
2023-05-09+23,243→ 23,243 total
Other
ACELYRIN, Inc.
Director Stock Option (right to buy)
2023-05-09−23,243→ 0 total
Award
ACELYRIN, Inc.
Director Stock Option (right to buy)
2023-05-04+23,243→ 23,243 total
Award
Day One Biopharmaceuticals, Inc.$DAWN
Director Stock Option (Right to buy Common Stock)
2022-06-21+28,700→ 28,700 total
Purchase
Day One Biopharmaceuticals, Inc.$DAWN
Common Stock
2021-06-01$16.00/sh+5,000→ 5,000 total
Award
Day One Biopharmaceuticals, Inc.$DAWN
Stock Option (right to buy Common Stock)
2021-05-26+63,000→ 63,000 total
Disposition from Tender
Pandion Therapeutics, Inc.
Common Stock
2021-04-01$60.00/sh−2,827,883→ 0 total
Disposition from Tender
Pandion Therapeutics, Inc.
Common Stock
2021-04-01$60.00/sh−1,000→ 0 total
Disposition to Issuer
Pandion Therapeutics, Inc.
Employee Stock Option (Right to Buy)
2021-04-01−13,997→ 0 total
Purchase
Pandion Therapeutics, Inc.
Common Stock
2020-11-19$15.12/sh+197,716→ 2,827,883 total
Purchase
Pandion Therapeutics, Inc.
Common Stock
2020-11-18$15.26/sh+14,197→ 2,630,167 total
Purchase
Pandion Therapeutics, Inc.
Common Stock
2020-11-17$15.43/sh+13,027→ 2,615,970 total
Purchase
Pandion Therapeutics, Inc.
Common Stock
2020-11-17$14.63/sh+2,170→ 2,602,943 total
Disposition to Issuer
Principia Biopharma Inc.
Director Stock Option (right to buy)
2020-09-28−10,240→ 0 total
Disposition to Issuer
Principia Biopharma Inc.
Director Stock Option (right to buy)
2020-09-28−20,475→ 0 total
Disposition to Issuer
Principia Biopharma Inc.
Director Stock Option (right to buy)
2020-09-28−10,240→ 0 total
Disposition from Tender
Principia Biopharma Inc.
Common Stock
2020-09-28$100.00/sh−667,600→ 0 total
Purchase
Pandion Therapeutics, Inc.
Common Stock
2020-07-21$18.00/sh+1,000→ 1,000 total
Conversion
Pandion Therapeutics, Inc.
Common Stock
2020-07-21+1,878,551→ 1,878,551 total
Conversion
Pandion Therapeutics, Inc.
Series B Preferred Stock
2020-07-21−9,579,462→ 0 total
Purchase
Pandion Therapeutics, Inc.
Common Stock
2020-07-21$18.00/sh+722,222→ 2,600,773 total
Award
Pandion Therapeutics, Inc.
Stock Option (right to buy)
2020-07-17+13,997→ 13,997 total
Award
Principia Biopharma Inc.
Director Stock Option (right to buy)
2020-06-04+10,240→ 10,240 total
Purchase
Principia Biopharma Inc.
Common Stock
2019-11-20$29.94/sh+55,000→ 667,600 total
Purchase
Principia Biopharma Inc.
Common Stock
2019-10-29$33.98/sh+9,196→ 612,600 total
Purchase
Principia Biopharma Inc.
Common Stock
2019-10-28$33.41/sh+68,404→ 603,404 total
Purchase
Principia Biopharma Inc.
Common Stock
2019-10-18$28.00/sh+535,000→ 535,000 total
Award
Principia Biopharma Inc.
Director Stock Option (right to buy)
2019-06-11+10,240→ 10,240 total
Conversion
Principia Biopharma Inc.
Series B-2 Convertible Preferred Stock
2018-09-18−260,617→ 0 total
Conversion
Principia Biopharma Inc.
Common Stock
2018-09-18+312,741→ 1,383,512 total
Conversion
Principia Biopharma Inc.
Series C Convertible Preferred Stock
2018-09-18−167,537→ 0 total
Conversion
Principia Biopharma Inc.
Series B-3 Convertible Preferred Stock
2018-09-18−544,047→ 0 total
Conversion
Principia Biopharma Inc.
Series B-1 Convertible Preferred Stock
2018-09-18−312,741→ 0 total
Conversion
Principia Biopharma Inc.
Common Stock
2018-09-18+1,070,771→ 1,070,771 total
Conversion
Principia Biopharma Inc.
Common Stock
2018-09-18+167,537→ 167,537 total
Conversion
Principia Biopharma Inc.
Common Stock
2018-09-18+260,617→ 1,644,129 total
Conversion
Principia Biopharma Inc.
Common Stock
2018-09-18+544,047→ 2,188,176 total
Purchase
Principia Biopharma Inc.
Common Stock
2018-09-18$17.00/sh+270,000→ 437,537 total
Conversion
Principia Biopharma Inc.
Series A Convertible Preferred Stock
2018-09-18−1,070,771→ 0 total
Award
Principia Biopharma Inc.
Director Stock Option (right to buy)
2018-09-13+20,475→ 20,475 total

Companies

Recent Filings

Address

C/O ACELYRIN, INC. 4149 LIBERTY CANYON RD.

AGOURA HILLS, CA, 91301

View on SEC.gov